A bottle of antidepressant pills
A bottle of antidepressant pills

Anti-depressants can change how the brain works in just hours

Researchers hope study could help patients who do not respond to them

Kashmira Gander
Friday 19 September 2014 18:59
Comments

Anti-depressant medication can affect a patient’s brain in just three hours, according to a new study.

Scientists tested the widely-prescribed drug escitalopram - marketed as Cipralex in the UK, or Lexapro in the US - which contains a serotonin re-uptake inhibitor (SSRI).

Seratonin is a neurotransmitter, a type of messenger chemical, that carries signals between nerve cells in the brain. SSRIs work by allowing more serotonin to pass messages between nearby nerve cells, according to the NHS.

It was previously understood that SSRIs affect a patient over a period of weeks, but a study by scientists from the Max Planck Institute for Human Cognitive and Brain Sciences in Germany published in the journal ‘Current Biology’ shows it could take as little as three hours.

To make their findings, scientists scanned the brains of volunteers who had taken escitalopram to measure their blood flow.

The results showed that the drug reduced connectivity in the majority of the brain - with an increase in brain connectivity in the cerebellum and thalamus regions.

"We were not expecting the SSRI to have such a prominent effect on such a short time scale or for the resulting signal to encompass the entire brain," said study leader Dr Julia Sacher, from the Max Planck Institute for Human Cognitive and Brain Sciences in Germany, Mail Online reported.

While doctors widely prescribe SSRIs, it is still not entirely clear how they work.

Dr Sacher said: "What we are seeing in medication-free individuals who had never taken antidepressants before may be an early marker of brain reorganisation.”

She added the new findings could be an essential first step toward clinical studies in patients suffering from depression. Researchers now hope to compare the brains of recovering patients, and those who fail to respond to SSRI treatment.

Dr Sacher said: "Understanding the differences between the brains of individuals who respond to SSRIs and those who don't could help to better predict who will benefit from this kind of antidepressant versus some other form of therapy.

"We hope our work will help to guide better treatment decisions and tailor individualised therapy for patients suffering from depression."

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in